GCG and diabetes mellitus: The individual properties of the various GLP-1 RAs might allow incretin-based treatment of type 2 diabetes mellitus to be tailored to each patient’s needs.25 The once-weekly dosing interval of the novel GLP-1 RA may be an advantage for patients who present barriers to a once-daily injectable therapy and may give patients also more freedom to live a flexible life without daily therapeutic actions.